Mozart Therapeutics, Inc.’s Post

View organization page for Mozart Therapeutics, Inc., graphic

2,561 followers

We’re pleased to announce that clinical development is underway for MTX‑101, our novel autoimmune checkpoint inhibitor! The Phase 1a/b clinical study is ongoing in healthy adults, and plans to include patients with celiac disease and type 1 diabetes. This significant milestone brings us closer to our goal of changing the treatment paradigm for those affected by autoimmune diseases. https://lnkd.in/gxnazZqg

  • No alternative text description for this image
Celine Jacquemont

Executive Director, Head of Translational Sciences

4mo

Congrats to the team ! Wishing you the best results for the first phase of the trial !

Like
Reply
Sarah Noonberg

Chief Medical Officer at Metagenomi

4mo

Congratulations Katie and team, such exciting news!

Like
Reply
Kamal D. Puri

Chief Scientific Officer at OncoResponse, Inc.

4mo

Congratulations Jason and the team!

Like
Reply
Andreas Wallnoefer

Senior Executive - Board Director and Advisor in Biotech and Pharma

4mo

Very interesting

Like
Reply
Jenny Miller

Sr Director, Head of Supply Chain, Logistics and Packaging

4mo

Congratulations!!!

Like
Reply
Lily Siravo

Vice President at The Higgins Group

4mo

Congratulations!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics